ARGX Q4 2022 Earnings — argenx SE Revenue & Financial Results | Market Cap Arena

ARGXargenx SE

$46B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$303M+1063.3% YoY

Gross Profit

-$78M-25.6% margin

Operating Income

-$302M-99.6% margin

Net Income

-$256M-84.4% margin

EPS (Diluted)

$-4.62

Cash Flow

Operating Cash Flow

-$344M

Free Cash Flow

-$345M

Stock-Based Comp.

$75M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$321M

Stockholders' Equity

$2.8B

Cash & Equivalents

$801M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$303M	$26M	+1063.3%
Gross Profit	-$78M	-$243M	+68.1%
Operating Income	-$302M	-$390M	+22.6%
Net Income	-$256M	-$414M	+38.3%